Sugi Predict

Sugi Predict / Compounds / SCHEMBL516689

SCHEMBL516689

SCHEMBL516689

Nc1ccc2[nH]c(-c3ccccc3)nc2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.76
▸ MAPT P10636 9/20 0.76
▸ SMN1; SMN2 Q16637 8/20 0.76
▸ KDM4E B2RXH2 8/20 0.76
▸ HPGD P15428 8/20 0.76
▸ NPC1 O15118 7/20 0.76
▸ RAB9A P51151 7/20 0.76
▸ GAA P10253 5/20 0.76
▸ GFER P55789 4/20 0.76
▸ GLA P06280 3/20 0.76
▸ HTT P42858 2/20 0.76
▸ RCE1 Q9Y256 1/20 0.76
▸ HSD17B10 Q99714 6/20 0.65
▸ TP53 P04637 5/20 0.65
▸ POLB P06746 3/20 0.65
▸ PRMT1 Q99873 1/20 0.62
▸ MEN1 O00255 6/20 0.62
▸ KMT2A Q03164 6/20 0.62
▸ RXFP1 Q9HBX9 2/20 0.62
▸ CACNA1B Q00975 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31289476 0.97 ALDH1A1 (0.71) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL1655753 0.91 MEN1 (0.73) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL30533210 0.91 MEN1 (0.73) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL417825 0.90 ALDH1A1 (0.71) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL12351269 0.90 MEN1 (0.76) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL30307784 0.89 ALDH1A1 (0.74) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL28312335 0.89 ALDH1A1 (0.74) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL8769051 0.89 MEN1 (0.71) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL159873 0.89 ALDH1A1 (0.74) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL9767334 0.88 ALDH1A1 (0.77) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115678010-B Polyamide acid, polyimide resin and preparation method thereof 中国科学院过程工程研究所 2023-04-14 — — CN claimed
CN-115678010-A Polyamide acid, polyimide resin and preparation method thereof 中国科学院过程工程研究所 2023-02-03 — — CN claimed
EP-4733300-A1 NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF Korea University Research and Business Foundation (KR) 2026-04-29 — — EP disclosed
WO-2024263007-A1 NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 고려대학교 산학협력단 2024-12-26 — — WO disclosed
WO-2024219864-A1 NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF 주식회사 넷타겟 2024-10-24 — — WO disclosed
CN-113736082-B Polyimide resin for negative photoresist and negative photoresist comprising the same 上海极紫科技有限公司 2023-08-15 — — CN disclosed
CN-115678010-B Polyamide acid, polyimide resin and preparation method thereof 中国科学院过程工程研究所 2023-04-14 — — CN disclosed
CN-115678010-A Polyamide acid, polyimide resin and preparation method thereof 中国科学院过程工程研究所 2023-02-03 — — CN disclosed
US-20230002558-A1 REACTIVE POLYAMIDEIMIDE OLIGOMERS, METHODS, AND ARTICLES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2023-01-05 — — US disclosed
CN-113736082-A Polyimide resin for negative photoresist and negative photoresist comprising same 上海极紫科技有限公司 2021-12-03 — — CN disclosed
US-10399966-B2 Compounds for treatment of trypanosomes and neurological pathogens and uses thereof UNIVERSITY OF WASHINGTON (US) 2019-09-03 — — US disclosed
US-7674809-B2 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM S.P.A. (IT) 2010-03-09 — — US disclosed
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM SPA 2005-09-08 — — US disclosed
EP-1571142-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production Rottapharm S.p.A. (IT) 2005-09-07 — — EP disclosed
WO-2005030206-A1 ARYL-1,3-AZOLE DERIVATIVES AND METHODS FOR INHIBITING HEPARNASE ACTIVITY IMCLONE SYSTEMS INCORPORATED (US) 2005-04-07 — — WO disclosed
EP-0843671-A1 HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 1998-05-27 — — EP disclosed
WO-1997003069-A1 HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 1997-01-30 — — WO disclosed
US-4716168-A STIMULANTS OF IMMUNE RESPONSE NORWICH EATON PHARMACEUTICALS, INC. (US) 1987-12-29 — — US disclosed
EP-0187705-A2 Imidazo(4,5-f)quinolines useful as immunomodulating agents Norwich Eaton Pharmaceuticals, Inc. (US) 1986-07-16 — — EP disclosed
US-3947434-A 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines MORTON-NORWICH PRODUCTS, INC. (US) 1976-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10399966-B2 Compounds for treatment of trypanosomes and neurological pathogens and uses thereof TSPO, GBA1, NLN ALDH1A1 2253/4885MAPT 364/4885SMN1; SMN2 361/4885
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production NOS3, NOS1, NOS2 ALDH1A1 1195/4885MAPT 4542/4885SMN1; SMN2 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.